Association between cancer history and second-generation drug-eluting stent thrombosis: insights from the REAL-ST registry

Background Cancer-associated thrombosis is a frequent complication of cancer; however, little evidence is available regarding the association between cancer history and coronary artery stent thrombosis (ST).

We aimed to investigate the relationship between cancer history and second-generation drug-eluting stent thrombosis (G2-ST).

Methods From the REAL-ST (Retrospective Multicenter Registry of ST After First- and Second-Generation Drug-Eluting Stent Implantation) registry, this study evaluated 1265 patients (G2- ST cases, n  = 253; controls, n  = 1012) with cancer-related information available.

Results The prevalence of patients with cancer history was higher (12.3% vs. 8.5%, p  = 0.065), and that of currently diagnosed and currently treated cancer was significantly higher in ST cases than controls (3.6% vs. 1.4%, p  = 0.021; 3.2% vs. 1.3%, p  = 0.037, respectively).

Multivariable logistic regression analysis revealed that cancer history was associated with late ST (odds ratio [OR]: 2.80, 95% confidence intervals [CI]: 0.92–8.55, p  = 0.071) and very late ST (OR: 2.40, 95% CI: 1.02-5.65, p  = 0.046), but not with early ST (OR: 1.01, 95% CI: 0.51-2.00, p  = 0.97).

During the median follow-up period of 872 days after the index ST events, patients with cancer history showed a higher mortality than those without, among both ST cases (hazard ratio [HR]: 1.93, 95% CI: 1.06-3.51, p  = 0.031) and controls (HR: 1.93, 95% CI: 1.09-3.40, p  = 0.023).

Conclusion A post hoc analysis of REAL-ST registry revealed that patients with G2-ST had a higher prevalence of currently diagnosed and currently treated cancer.

Notably, cancer history was associated with the occurrence of late and very late ST, but not with early ST.